CN108323184A - 验证生物标志物测量 - Google Patents

验证生物标志物测量 Download PDF

Info

Publication number
CN108323184A
CN108323184A CN201680043261.9A CN201680043261A CN108323184A CN 108323184 A CN108323184 A CN 108323184A CN 201680043261 A CN201680043261 A CN 201680043261A CN 108323184 A CN108323184 A CN 108323184A
Authority
CN
China
Prior art keywords
value
control value
biomarker
biomarker values
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680043261.9A
Other languages
English (en)
Chinese (zh)
Inventor
里奥·查尔斯·麦克休
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunexpress Pty Ltd
Original Assignee
Immunexpress Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901982A external-priority patent/AU2015901982A0/en
Application filed by Immunexpress Pty Ltd filed Critical Immunexpress Pty Ltd
Publication of CN108323184A publication Critical patent/CN108323184A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Bioethics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201680043261.9A 2015-05-28 2016-05-20 验证生物标志物测量 Pending CN108323184A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901982 2015-05-28
AU2015901982A AU2015901982A0 (en) 2015-05-28 Validating biomarker measurement
PCT/AU2016/050388 WO2016187655A1 (en) 2015-05-28 2016-05-20 Validating biomarker measurement

Publications (1)

Publication Number Publication Date
CN108323184A true CN108323184A (zh) 2018-07-24

Family

ID=57392259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680043261.9A Pending CN108323184A (zh) 2015-05-28 2016-05-20 验证生物标志物测量

Country Status (9)

Country Link
US (2) US20180107783A1 (cg-RX-API-DMAC7.html)
EP (1) EP3304093B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018525703A (cg-RX-API-DMAC7.html)
CN (1) CN108323184A (cg-RX-API-DMAC7.html)
AU (1) AU2016267392B2 (cg-RX-API-DMAC7.html)
CA (1) CA2986787A1 (cg-RX-API-DMAC7.html)
DK (1) DK3304093T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016187655A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109374904A (zh) * 2018-10-29 2019-02-22 浙江医院 一种蛋白质类脓毒症标志物及其在严重脓毒症早期预警的应用及其筛选方法
CN110408692A (zh) * 2018-09-14 2019-11-05 北京泱深生物信息技术有限公司 血液中的分子作为诊断脓毒症的标志物
CN113488107A (zh) * 2021-07-07 2021-10-08 广州华银健康医疗集团股份有限公司 筛选免疫组库测序生物标志物的方法、设备和存储介质
CN114628024A (zh) * 2022-02-24 2022-06-14 重庆市急救医疗中心(重庆市第四人民医院、重庆市急救医学研究所) 一种生物标志物组在制备用于辅助筛查脓毒症的产品中的用途和辅助筛查方法及其系统
CN114829882A (zh) * 2019-11-05 2022-07-29 阿比尔技术公司 植物产品中感染的预测
US12462902B2 (en) 2020-02-12 2025-11-04 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180107783A1 (en) * 2015-05-28 2018-04-19 Immunexpress Pty Ltd Validating biomarker measurement
CA3002196C (en) * 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
CN111033631B (zh) * 2017-06-13 2024-03-12 波士顿基因公司 用于生成分子功能谱、对其进行可视化和分类的系统和方法
AU2018312117B2 (en) * 2017-08-04 2022-05-12 Billiontoone, Inc. Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
WO2021202620A1 (en) * 2020-03-31 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Metabolomics approach combined with machine learning to recognize a medical condition
EP4195212A1 (en) * 2021-12-08 2023-06-14 A3P Biomedical AB (publ) Certainty-based medical conclusion model adaptation
WO2025094604A1 (ja) * 2023-10-31 2025-05-08 アークレイ株式会社 検知方法、検知装置、検知システム、検知プログラム、及び記録媒体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180365A1 (en) * 2002-12-13 2004-09-16 Affymetrix, Inc. Methods and computer software products for gene expression data quality analysis
US20090203534A1 (en) * 2005-10-21 2009-08-13 Hamid Hossain Expression profiles for predicting septic conditions
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
CN103620019A (zh) * 2011-04-18 2014-03-05 迪阿米尔有限责任公司 基于miRNA的通用筛选试验(UST)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148339A1 (en) 2001-05-07 2003-08-07 Hrissi Samartzidou Artificial genes for use as controls in gene expression analysis systems
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2006023769A2 (en) 2004-08-18 2006-03-02 Abbott Molecular, Inc. Determining data quality and/or segmental aneusomy using a computer system
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン,ディッキンソン アンド カンパニー 敗血症の診断
US20070255113A1 (en) * 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
US20080213768A1 (en) * 2006-08-17 2008-09-04 Zhauhui Cai Identification and use of biomarkers for non-invasive and early detection of liver injury
DE102007010252B4 (de) 2007-03-02 2013-07-04 Sirs-Lab Gmbh Kontrollgene zur Normalisierung von Genexpressionsanalysedaten
CA2604317C (en) * 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
JP4666237B2 (ja) 2008-07-09 2011-04-06 ソニー株式会社 遺伝子検定方法、遺伝子検定プログラム及び遺伝子検定装置
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
WO2011139901A1 (en) 2010-04-29 2011-11-10 Esoterix Genetic Laboratories, Llc Gc wave correction for array-based comparative genomic hybridization
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
EP3255435A1 (en) * 2012-04-13 2017-12-13 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
CN105518153A (zh) 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定
WO2015117204A1 (en) * 2014-02-06 2015-08-13 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
US20180107783A1 (en) * 2015-05-28 2018-04-19 Immunexpress Pty Ltd Validating biomarker measurement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180365A1 (en) * 2002-12-13 2004-09-16 Affymetrix, Inc. Methods and computer software products for gene expression data quality analysis
US20090203534A1 (en) * 2005-10-21 2009-08-13 Hamid Hossain Expression profiles for predicting septic conditions
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
CN103620019A (zh) * 2011-04-18 2014-03-05 迪阿米尔有限责任公司 基于miRNA的通用筛选试验(UST)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110408692A (zh) * 2018-09-14 2019-11-05 北京泱深生物信息技术有限公司 血液中的分子作为诊断脓毒症的标志物
CN109374904A (zh) * 2018-10-29 2019-02-22 浙江医院 一种蛋白质类脓毒症标志物及其在严重脓毒症早期预警的应用及其筛选方法
CN114829882A (zh) * 2019-11-05 2022-07-29 阿比尔技术公司 植物产品中感染的预测
CN114829882B (zh) * 2019-11-05 2023-02-28 阿比尔技术公司 植物产品中感染的预测
US12380965B2 (en) 2019-11-05 2025-08-05 Apeel Technology, Inc. Prediction of infection in plant products
US12462902B2 (en) 2020-02-12 2025-11-04 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
CN113488107A (zh) * 2021-07-07 2021-10-08 广州华银健康医疗集团股份有限公司 筛选免疫组库测序生物标志物的方法、设备和存储介质
CN113488107B (zh) * 2021-07-07 2022-07-19 广州华银康医疗集团股份有限公司 筛选免疫组库测序生物标志物的方法、设备和存储介质
CN114628024A (zh) * 2022-02-24 2022-06-14 重庆市急救医疗中心(重庆市第四人民医院、重庆市急救医学研究所) 一种生物标志物组在制备用于辅助筛查脓毒症的产品中的用途和辅助筛查方法及其系统

Also Published As

Publication number Publication date
US10719579B2 (en) 2020-07-21
DK3304093T3 (da) 2024-02-12
EP3304093A1 (en) 2018-04-11
JP2018525703A (ja) 2018-09-06
CA2986787A1 (en) 2016-12-01
EP3304093B1 (en) 2023-12-27
HK1249182A1 (zh) 2018-10-26
WO2016187655A1 (en) 2016-12-01
US20160350477A1 (en) 2016-12-01
AU2016267392A1 (en) 2017-12-07
EP3304093A4 (en) 2019-02-06
AU2016267392B2 (en) 2021-12-09
US20180107783A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
EP3304093B1 (en) Validating biomarker measurement
US20210040562A1 (en) Methods for evaluating lung cancer status
US20150080243A1 (en) Methods and compositions for detecting cancer based on mirna expression profiles
US20210166813A1 (en) Systems and methods for evaluating longitudinal biological feature data
US20150088430A1 (en) Methods for evaluating lung cancer status
JP2020522690A (ja) 肺疾病の特定又はモニタリング方法及びシステム
US12297505B2 (en) Algorithms for disease diagnostics
WO2013049152A2 (en) Methods for evaluating lung cancer status
Xie et al. 3 CpG methylation biomarkers for the diagnosis of polycystic ovary syndrome (PCOS) in blood samples
US20240035090A1 (en) mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE
AU2024210217A1 (en) Methods and systems for detecting and assessing liver conditions
US20250305051A1 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
Berndt et al. A multivariate cell-based assay for blood-based diagnostics enhances lung cancer risk stratification
CN119252381A (zh) 基于生物标志物的腹膜后脂肪肉瘤分子分型方法、系统及设备

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180724